Pleurodesis is a procedure performed to obliterate the pleural space to prevent recurrent pleural effusions, pneumothorax, or to treat a persistent pneumothorax. Pleurodesis is commonly accomplished by draining the pleural fluid or intrapleural air followed by either a mechanical procedure or instilling a chemical irritant into the pleural space, which causes intense inflammation and fibrosis subsequently leading to adhesions between the two pleural membranes. Pleurodesis is most commonly used for recurrent malignant pleural effusions, e.g., in the metastatic breast or ovarian cancer and lung cancer. Due to the limited life expectancy of these patients, the purpose of the therapy is to minimize dyspnea, patient discomfort, length of hospital stay, and overall treatment cost. There are two types of pleurodesis
Pleura is a membrane surrounding the lung. It is composed of the visceral pleura and the parietal pleura with a potential space between the two membranes referred to as the pleural space. Under physiological conditions, approximately 50 ml of pleural fluid exists in the pleural space. Under pathological conditions, air or excess pleural fluid can build up in the pleural space. When such a process becomes recurrent and contributing to significant symptoms, procedures such as pleurodesis are indicated.
The most common indication for pleurodesis is a malignant pleural effusion, which is typically refractory. Other indications for pleurodesis are recurrent pneumothorax and recurrent pleural effusions. While there are many management options for the treatment of these pleural diseases, the decision to proceed with pleurodesis should be carefully undertaken after discussion with the patient and reviewing expectations from the procedure. A medical pleurodesis is a preferred approach for patients.
Indications for chemical pleurodesis are malignant pleural effusions, refractory symptomatic non-malignant pleural effusions (chronic ambulatory peritoneal dialysis, chylothorax, nephrotic syndrome, lupus, hepatic hydrothorax, and heart failure), recurrent primary pneumothorax and recurrent secondary pneumothorax.
Indications for mechanical pleurodesis are similar to chemical pleurodesis with the added benefit of treating underlying cause if present during the same procedure. For example, the simultaneous inspection and resection of subpleural blebs and bullae, which could be the source of recurrent pneumothoraces.
Since successful pleurodesis requires physical contact between the visceral and parietal pleura, any disease process that would interfere with complete lung expansion (e.g., trapped lung, insufficient drainage) would lead to failure of pleurodesis. Pleural manometry at the time of therapeutic thoracentesis can help in the identification of unexpandable lung. Manometry measures pleural pressure changes as pleural fluid is withdrawn and allows the calculation of pleural elastance at the end of the procedure. A final value for pleural elastance ≥19 cmH2O per liter of fluid removed indicates a high likelihood of an unexpandable lung and predicts pleurodesis failure. Hence medical pleurodesis is generally contraindicated in such patients, and mechanical pleurodesis would be the preferred approach. Individual exceptions may apply to patients with very small loculated pneumothoraces or patients who decline mechanical pleurodesis.
Other risk factors for unsuccessful pleurodesis include previous thoracic irradiation and a chest tube duration of more than ten days, while risk factors for death included a Karnofsky index <50 percent, a body mass index <25 kg/meter square, malignancy, and male gender. Patients with a life expectancy of fewer than three months should not be treated with pleurodesis and can be managed with repeated thoracentesis as required to relieve dyspnea.
Other contraindications include a lack of consent from the patient, more than 150 ml of fluid output through chest drain, and pleural infection.
Following are the sclerosing agents that can be used as chemicals for chemical pleurodesis:
The choice among these agents is determined by several factors, including local expertise, availability of individual agents, and the underlying process for which chemical pleurodesis is needed. The sclerosing agent is delivered via a chest tube, which varies from large bore (e.g., 24 French) or a small bore (e. g. 12 French) into the pleural cavity. The other equipment required for pleurodesis besides sclerosing agent include:
While pulmonologists can perform medical pleurodesis at the bedside under local anesthesia, mechanical pleurodesis is performed under general anesthesia during open thoracotomy or video-assisted thoracoscopic surgery (VATS) in an operating room by a thoracic surgeon.
Informed consent from the patient should be obtained with an explicit discussion on the indications, alternatives, risks, and complications of the procedure. The procedural site should be marked, and NPO status should be confirmed. An appropriate plan for sedation and anesthesia should be established. For chemical pleurodesis, a patent chest tube should be in situ, lung should be expanded to the chest wall, and fluid output from the chest drain should be less than 100 ml in the last 24 hours.
The type of pleurodesis (chemical versus mechanical), sclerosing agent (talc - talc slurry over talc poudrage versus other), chest tube size (large- vs. small-bore) and choice of analgesic agent (opiate versus nonsteroidal anti-inflammatory [NSAID]) varies considerably among centers and experts. The preferred method is small-bore chest tubes since they are also well tolerated by patients and treatment with opioids or NSAID analgesia.
So other approaches that use thoracoscopic administration of talc by poudrage, talc slurry by large-bore chest tubes, or performance of thoracoscopic mechanical pleural abrasion followed by continued drainage with a large-bore chest tube appear to be effective options.
Chemical pleurodesis refers to the obliteration of the pleural space by the induction of pleural inflammation and fibrosis using a sclerosant (most commonly talc). The sclerosant can be instilled via a small- or large-bore chest tube or indwelling catheter (talc slurry), or it can be administered at the time of thoracoscopy (video-assisted thoracoscopy or pleuroscopy) or thoracotomy (talc insufflation/poudrage). The preferred method usually is chemical pleurodesis via a small-bore chest tube rather than via thoracoscopy because the former is as effective, less invasive, and better tolerated.
Chest Tube Size and Drainage:
The procedure of Chemical Pleurodesis
Wear sterile gloves, clean the chest tube and area around it with povidone or any sterilizing agent. Place sterile dressing under chest drain and three-way stopper. Remove the cap to the three-way stopper and clean. Fill 1% lignocaine in a syringe and attach to the three-way tap and instill lignocaine in the pleural cavity. Turn off three-way stopper remove the syringe. In 50 ml syringe, mix the sclerosing agent like talc in 40 ml of normal saline and shake well. It is challenging to dissolve the talc, and once the slurry is made, so do not stop moving the syringe, or the talc will precipitate out. Instill the slurry into the pleural cavity via a chest tube and flush immediately with 10 ml normal saline. Close the three-way stopper and leave it closed for three hours.
It is mechanical abrasion (also termed dry abrasion) of the parietal pleura during thoracoscopy or thoracotomy or placement of a tunneled pleural catheter, which drains pleural fluid and may induce pleurodesis without instillation of a sclerosing agent.
Patients must be good surgical candidates and have a reasonably long expected survival because total radical pleurectomy/decortication requires a thoracotomy and is a major surgical procedure associated with considerable morbidity and some mortality.
The success of pleurodesis depends on many factors. Failure of the procedure may be due to increased tumor burden, which causes a decrease in the mesothelial cells and, therefore, an inadequate inflammatory response. The type of tumor may also play a role in the process, diffuse mesothelioma and metastatic carcinomas have an inadequate response. This is because the healthy mesothelial cells secrete the inflammatory mediators necessary for fibrosis.
Systemic inflammation and acute respiratory distress syndrome (ARDS) have been reported in patients receiving talc. Inflammation occurs due to the increased systemic absorption of talc, especially with smaller particle size, and a large dose of talc.
Patients can develop a fever after pleurodesis; this is due to the inflammatory response of the body. Patients can also have an anaphylactic reaction to any of the chemical sclerosing agent. Pleural infection can occur if aseptic techniques are not followed.
In the case of surgical pleurodesis, there can be complications of general anesthesia, wound infection, atelectasis, etc.
For most patients with good performance status who are symptomatic, malignant pleural effusion re-accumulates rapidly (e.g., less than one month), we suggest drainage via an indwelling pleural catheter or chemical pleurodesis by the catheter or by either thoracoscopy or pleuroscopy, rather than repeat therapeutic thoracentesis.
The management of pleural disease is complex and often poses a management dilemma. This usually requires a multidisciplinary team and inter-professional communication between specialists in pulmonary medicine, thoracic surgery, and oncology, especially in patients with malignancy as an etiology of the disease. The decision to perform pleurodesis should be undertaken after careful discussion between the patient and the medical team. The nurse plays an essential role in the management of the patient in the preoperative and postoperative phases in terms of education of the patient and family, control of postoperative pain, and early mobilization after the procedure. To improve patient selection and outcomes after pleurodesis, an inter-professional team is exceptionally vital and integral to the safety of this complicated procedure.
|||Banini BA,Alwatari Y,Stovall M,Ogden N,Gershman E,Shah RD,Strife BJ,Shojaee S,Sterling RK, Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance. Hepatology (Baltimore, Md.). 2020 Jun 25; [PubMed PMID: 32585037]|
|||West SD,Davies RJ,Lee YC, Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Current opinion in pulmonary medicine. 2004 Jul [PubMed PMID: 15220757]|
|||Shaw P,Agarwal R, Pleurodesis for malignant pleural effusions. The Cochrane database of systematic reviews. 2004 [PubMed PMID: 14973997]|
|||Asban A,Raza SS,McLeod C,Donahue J,Wei B, Mechanical or chemical and mechanical pleurodesis for spontaneous pneumothorax: what is the most effective approach in preventing recurrence? A systematic review and meta-analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2020 May 27; [PubMed PMID: 32463893]|
|||Yeung M,Loh EW,Tiong TY,Tam KW, Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis. Clinical [PubMed PMID: 32524317]|
|||Shafiq M,Feller-Kopman D, Management of Malignant Pleural Effusions. Clinics in chest medicine. 2020 Jun; [PubMed PMID: 32402361]|
|||Terra RM,Dela Vega AJM, Treatment of malignant pleural effusion. Journal of visualized surgery. 2018; [PubMed PMID: 29963399]|
|||Rodriguez-Panadero F,Romero-Romero B, Management of malignant pleural effusions. Current opinion in pulmonary medicine. 2011 Jul [PubMed PMID: 21519264]|
|||Roberts ME,Neville E,Berrisford RG,Antunes G,Ali NJ, Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug; [PubMed PMID: 20696691]|
|||Chan JYH,Lee YCG, Pleurodesis and systemic inflammatory markers: Lessons and insights. Respirology (Carlton, Vic.). 2020 Jul; [PubMed PMID: 31945800]|
|||Olesen WH,Katballe N,Sindby JE,Titlestad IL,Andersen PE,Lindahl-Jacobsen R,Licht PB, Surgical treatment versus conventional chest tube drainage in primary spontaneous pneumothorax: a randomized controlled trial. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2018 Jul 1; [PubMed PMID: 29509892]|
|||Burki TK, NSAIDs versus opioids and chest tube size in pleurodesis. The Lancet. Respiratory medicine. 2016 Feb; [PubMed PMID: 26868872]|
|||Rahman NM,Pepperell J,Rehal S,Saba T,Tang A,Ali N,West A,Hettiarachchi G,Mukherjee D,Samuel J,Bentley A,Dowson L,Miles J,Ryan CF,Yoneda KY,Chauhan A,Corcoran JP,Psallidas I,Wrightson JM,Hallifax R,Davies HE,Lee YC,Dobson M,Hedley EL,Seaton D,Russell N,Chapman M,McFadyen BM,Shaw RA,Davies RJ,Maskell NA,Nunn AJ,Miller RF, Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. JAMA. 2015 Dec 22-29; [PubMed PMID: 26720026]|
|||Guinde J,Georges S,Bourinet V,Laroumagne S,Dutau H,Astoul P, Recent developments in pleurodesis for malignant pleural disease. The clinical respiratory journal. 2018 Oct; [PubMed PMID: 30252207]|
|||Mierzejewski M,Korczynski P,Krenke R,Janssen JP, Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration. Respiratory research. 2019 Nov 7; [PubMed PMID: 31699094]|
|||Wollbrett C,Seitlinger J,Renaud S, Delivery of Talc for Pleurodesis of Malignant Pleural Effusions. JAMA. 2020 May 12; [PubMed PMID: 32396177]|
|||Rodriguez-Panadero F,Montes-Worboys A, Mechanisms of pleurodesis. Respiration; international review of thoracic diseases. 2012; [PubMed PMID: 22286268]|
|||Genofre EH,Vargas FS,Acencio MM,Antonangelo L,Teixeira LR,Marchi E, Talc pleurodesis: evidence of systemic inflammatory response to small size talc particles. Respiratory medicine. 2009 Jan; [PubMed PMID: 18789662]|